Benzinga | Jan 8, 2021 08:38AM EST

JP Morgan Downgrades Sarepta Therapeutics to Underweight, Announces $96 Price Target

JP Morgan downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Overweight to Underweight and announces $96 price target.